Bhanu Gupta, MD
Cardiovascular Disease · Seattle, WANPI 1437314903
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Bayer accounts for 81.6% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $22,877, more than ten times the $629 reported in 2019. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $354.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$22K
- Abiomed$2K
- Abbott$1K
- Edwards Lifesciences$317
- Medtronic$264
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$255
- plus $721 from 13 others
Across 30 payments — averaging $4003.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$73K
- Edwards Lifesciences$23K
- Boston Scientific$18K
- Cvrx, Inc.$6K
What the payments were for
- Consulting fees$6,44424%
- Speaking & faculty fees$13,57250%
- Travel & lodging$2,4889%
- Food & beverage$4,42816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 11 | $21,974 |
| Abiomed | 12 | $2,085 |
| Abbott | 15 | $1,316 |
| Edwards Lifesciences | 3 | $317 |
| Medtronic(2 entities) | 3 | $264 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $255 |
| Boston Scientific | 3 | $243 |
| Alnylam Pharmaceuticals Inc. | 2 | $138 |
| Novartis | 6 | $127 |
| Pfizer | 3 | $40 |
| Merck | 1 | $32 |
| Irhythm Technologies, Inc. | 1 | $31 |
| Amgen | 2 | $28 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| Sensible Medical Innovations Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$21,800
- Impella$1,615
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$510
- CARDIOMEMS$333
- LifeVest$194
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$143
- Avalus$130
- SAPIEN 3 Ultra RESILIA$128
- Watchman$121
- Resolute$116
- ONPATTRO$116
How this compares
$26,932 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 16 | $359,928 |
| JardianceEmpagliflozin | 109 | $114,834 |
| EntrestoSacubitril/Valsartan | 96 | $114,311 |
| XareltoRivaroxaban | 30 | $33,633 |
| EliquisApixaban | 38 | $32,097 |
| FarxigaDapagliflozin Propanediol | 21 | $28,010 |
| Metoprolol Succinate | 168 | $2,742 |
| Spironolactone | 184 | $2,105 |
| Losartan Potassium | 90 | $867 |
| Furosemide | 110 | $729 |
| Amiodarone Hcl | 29 | $652 |
| Torsemide | 19 | $597 |
| Potassium Chloride | 37 | $537 |
| Atorvastatin Calcium | 33 | $425 |
| Carvedilol | 34 | $340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $40 | $392,02654 claims |
| Boehringer IngelheimJardiance | $12 | $114,834109 claims |
| NovartisEntresto | $127 | $114,31196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 cardiovascular disease providers in Washington.
Other cardiovascular disease in Seattle
- Mariko HarperSeattle$246K
- Gary OppenheimSeattle$153K
- Kelley BranchSeattle$103K
- Erik WissnerSeattle$67K
- Younghoon KwonSeattle$66K
- Aron BenderSeattle$60K
- Vidhushei YogeswaranSeattle$55K
- Santanu BiswasSeattle$30K
- Michael LongoSeattle$22K
- Oana PetrescuSeattle$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.